CombiMatrix Corporation is a provider of molecular diagnostic solutions. The Company specializes in pre-implantation genetic screening, miscarriage analysis, prenatal diagnosis and pediatric developmental disorders, offering deoxyribonucleic acid-based testing for the detection of genetic abnormalities, which cannot be identified through traditional methodologies. It performs genetic testing utilizing a range of cytogenomic techniques, including chromosomal microarray analysis, fluorescence in situ hybridization and karyotyping. Its prenatal and postnatal microarray focuses on diagnosing genomic syndromes associated with intellectual disability, developmental delays, congenital anomalies, dysmorphic features and autism spectrum disorders. It develops and markets its molecular testing services in approximately four markets, such as in vitro fertilization (IVF), miscarriage analysis (products of conception analysis), prenatal genetics and postnatal developmental disorders.
|Headquarters||310 Goddard Ste 150|
IRVINE, CA, United States 92618-4617
|Chairman of the Board, President, Chief Executive Officer||Robert Jessup|
|Chief Financial Officer, Treasurer, Secretary||Scott Burell|
|Director||Dirk van den Boom|
|Independent Director||Robert Hoffman|
|Shares Out.||2.9M||Book Value||$2.43|
|Annual Dividend Rate||0.00 USD||Price/Sales (TTM)||1.0|
|Ex-Div Date||1/1/01||P/Cash Flow (TTM)||--|
|Pay Date||1/1/01||Operating Margin||-31.81%|
*GAAP = prior to non-GAAP analyst adjusted earnings.